Sandoz Group (OTCMKTS:SDZNY) Reaches New 12-Month High – Still a Buy?

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $76.93 and last traded at $76.66, with a volume of 3549 shares trading hands. The stock had previously closed at $75.22.

Analysts Set New Price Targets

Separately, Barclays raised shares of Sandoz Group to a “strong-buy” rating in a research report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Sandoz Group presently has a consensus rating of “Moderate Buy”.

Sandoz Group Stock Up 3.9%

The company’s fifty day moving average is $71.48 and its 200-day moving average is $63.85. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.82 and a current ratio of 1.29.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.